2026: Steady Progress, Moving Forward with Purpose

Advancing Industry Standards and Enabling Regulated Growth

In 2025, TECH-INNO continued to deepen its engagement in industry standard development, leveraging professional expertise to support the sector’s transition toward greater standardization and intelligence:

• Co-published the 2025 Equol White Paper in collaboration with leading industry enterprises, providing authoritative guidance for research and application in the field;

• Participated in the drafting of the national standard “General Technical Requirements for Digital Food Factories,” contributing hands-on experience to the industry’s intelligent manufacturing upgrade;

• Actively contributed to the formulation of the group standard “Determination of Estrogen-Regulating Efficacy of Oral Health Products — Transgenic Medaka In Vivo Fluorescence Assay,” strengthening the scientific foundation for efficacy evaluation of oral health products.

Expanding Business Boundaries and Building a Diversified Growth Ecosystem

TECH-INNO achieved multi-dimensional breakthroughs in 2025 by continuously enriching its product portfolio, expanding market pathways, and constructing a diversified growth ecosystem:

· Technology Platform Deployment and Capacity Enhancement
An integrated efficacy technology service platform for both ingestible and topical applications was established, alongside the advancement of fermentation technologies for natural plants and their metabolites, providing core support for product innovation and scalable production.

· Product Portfolio Expansion Targeting High-Growth Segments
In collaboration with Bangshang, TECH-INNO successfully launched innovative products including StanYouth® Urolithin A, S-Equol, and Dihydroberberine, strategically positioning itself in high-potential sectors such as healthy aging and weight management.

· Dual Breakthroughs and New Ingredient Milestones
The cosmetics business achieved a major milestone as MitoYouth® Urolithin A obtained approval as a new cosmetic ingredient in China, further strengthening the company’s ingestible–topical integrated product layout.
In parallel, application technologies for LicorPure® Glabridin were upgraded, and a joint efficacy evaluation study was completed on the combined application of MitoYouth® Urolithin A and LicorPure® Glabridin for the repair of sensitive female skin.

· Enhanced Compliance and Certification to Strengthen Technical Barriers
Berberine successfully obtained U.S. SELF GRAS safety certification and completed a registered clinical study (NCT05720299). In addition, a mulberry leaf–berberine compound product was submitted for an international PCT patent application, further reinforcing market access advantages across multiple dimensions.

· Ecosystem Synergy and Global Resource Integration
Continued advancements were made in the herbal + probiotics domain. The AKK ingredient developed in collaboration with Zhiyi Biology progressed further toward application in functional foods. Meanwhile, a strategic partnership was established with international microbial technology leader Muen Bio, focusing on next-generation probiotics + herbal dual-brand ingredient development, enabling complementary strengths and expanded innovation boundaries.

Deepening Global Presence and Expanding Market Reach

In 2025, TECH-INNO actively engaged global markets, leveraging major industry exhibitions as platforms to showcase brand strength and product value while expanding its industry influence.

• Domestic market: Successful participation in three major exhibitions—HNC & CPHI 2025, FIC 2025, and NPEW 2025—facilitated precise engagement with domestic partners.

• International market: TECH-INNO made strong appearances at four leading global exhibitions, including SupplySide Global 2025 (USA) and Vitafoods Asia 2025 (Thailand), proactively connecting with high-quality global resources and laying a solid foundation for overseas business expansion.

Research-Driven Innovation Accelerating Industrialization

In 2024, TECH-INNO participated in the establishment of the Shengzhou–Soochow University Silk Fibroin Biomedical Application Industrialization Research Institute, creating a full-chain technical service platform spanning innovative R&D, pilot-scale transformation, and industrial implementation for novel silk fibroin biomaterials.

In 2025, the silk fibroin microneedle production line was officially completed, marking a critical step forward in the industrialization of silk fibroin-based biomaterials.

Strengthening Intellectual Property and Building Core Brand Barriers

Throughout 2025, TECH-INNO continued to reinforce its intellectual property strategy, using core technologies and brand assets to construct sustainable competitive barriers and provide long-term legal and brand support:

• 15 new patents added, covering key areas such as product development and technological innovation;

• 48 new trademarks registered, enhancing brand recognition and market influence.

TECH-INNO — Integrating Health More Seamlessly into Life.